Novavax Says Its Covid Vaccine More Than 90% Effective

Novavax, Inc. (NVAX) Monday said NVX-CoV2373, its Covid-19 vaccine candidate, met the primary end point in late-stage study.

The phase 3 study of NVX-CoV2373, dubbed Prevent-19, showed overall efficiency of 90.4%, achieving its primary endpoint, Novavax said.

The vaccine candidate showed 100% protection against moderate or severe disease, Novavax said. Vaccine efficacy remained 91% among "high-risk" populations.

The vaccine showed 93% efficacy against predominantly circulating Variants of Concern and Variants of Interest, and 100% efficacy against variants "not considered Variants of Concern/Interest".

The company plans to file for regulatory authorizations in the third quarter.

"Upon regulatory approvals, Novavax remains on track to reach manufacturing capacity of 100 million doses per month by the end of the third quarter and 150 million doses per month by the end of the fourth quarter of 2021," the company said.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
General Motors Co. (GM) said its second-quarter results were better than originally expected due to strong pricing and demand, record GM Financial results and improved near-term production from the pull forward of semiconductors from the third quarter. Based on first-half performance and expectations... PepsiCo, Inc. (PEP) has reached an agreement with private equity firm PAI Partners to sell Tropicana, Naked and other select juice brands across North America. The agreement also includes an irrevocable option to sell certain juice businesses in Europe. The combined pre-tax cash proceeds will be approximately... Drug major Eli Lilly And Co. reported Tuesday weak profit in its second quarter, despite higher revenues driven by strong volume across core business and most major geographies. Further, the company trimmed its forecast for fiscal 2021 earnings on a reported basis and margin, while maintained adjusted earnings view above market estimates. The company also tightened full-year revenue forecast.
Follow RTT